Q-omics provides the consensus-scored DDX18P5 profile across patient tissues and cancer cell-line models. DDX18P5 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, DDX18P5 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, DDX18P5 RNA expression shows 13,320 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, COAD, and GBM as cancer lineages where DDX18P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DDX18P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DDX18P5 survival associations across molecular data types. DDX18P5 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DDX18P5 RNA expression–survival associations across cancer types. High DDX18P5 expression shows unfavorable associations in LIHC, OV, MESO and UCS, but favorable associations in BLCA and LUAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for DDX18P5 RNA expression.
This table summarizes DDX18P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for DDX18P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DDX18P5 shows lower tumor expression in BRCA and THCA and higher tumor expression in COAD, STAD, BLCA and KICH. The COAD box plot shows higher DDX18P5 RNA expression in tumor versus normal tissue (log2 FC = +0.198, t-test p < 0.001).
This table shows molecular features associated with DDX18P5 in patient tissues and cancer cell lines. In patient samples, DDX18P5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
